Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Schatte

Urology Pasadena, TX Medical Doctor

NPI 1447308523 CMS profile 155834

3230 Strawberry Rd, Pasadena, TX 77504

Open in the dashboard

General payments

$8,214

309 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edward Schatte of Pasadena, TX is reported in the CMS Open Payments database as having received $8,214 across 309 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,123 47
2024 General $1,270 59
2023 General $1,160 51
2022 General $2,371 39
2021 General $1,113 46
2020 General $535 31
2019 General $642 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Schatte
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Edward Schatte were reported at $1,123. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Edward Schatte Urology median Middle half National median
2019 $642 $480 $147–$1,201 $163
2020 $535 $246 $87–$645 $114
2021 $1,113 $358 $111–$1,000 $132
2022 $2,371 $476 $143–$1,263 $149
2023 $1,160 $560 $168–$1,461 $160
2024 $1,270 $563 $170–$1,464 $164
2025 $1,123 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma Global Development $1,465 2 payments
  2. Astellas Pharma US Inc $1,222 60 payments
  3. AbbVie, Inc. $663 29 payments
  4. Pfizer Inc. $574 29 payments
  5. Medtronic, Inc. $465 22 payments
  6. Sumitomo Pharma America, Inc. $332 14 payments
  7. ABC Home Medical Supply, Inc. $308 11 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $292 11 payments
  9. Progenics Pharmaceuticals, Inc. $255 10 payments
  10. Endo Pharmaceuticals Inc. $225 14 payments
  11. Other $2,413 107 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,508 304 payments
  2. Consulting Fee $1,440 1 payment
  3. Education $267 4 payments
Products named General payments · program years 2019–2025
  1. XTANDI $2,660 67 payments
  2. ORGOVYX $451 22 payments
  3. INTERSTIM $444 21 payments
  4. LUPRON DEPOT $385 17 payments
  5. MYRBETRIQ $382 23 payments
  6. GEMTESA $382 17 payments
  7. Nubeqa $292 11 payments
  8. AVEED $279 16 payments
  9. XIAFLEX $279 16 payments
  10. Xofigo $263 10 payments
  11. Other $3,576 165 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

3,406

Median for Urology: 1,053

Drug cost

$506,704

Median for Urology: $101,464

Branded share of claims

25.1%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 25 $321,188
Myrbetriq Mirabegron Brand 122 $124,239
Tamsulosin Hcl Generic 977 $12,654
Finasteride Generic 651 $8,176
Dutasteride-Tamsulosin Dutasteride/Tamsulosin Hcl Brand 36 $6,967
Solifenacin Succinate Generic 113 $5,907
Oxybutynin Chloride Generic 226 $5,576
Dutasteride Generic 155 $5,054
Trospium Chloride Generic 23 $2,935
Silodosin Generic 19 $2,418

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$103,300

Medicare's payments for the services billed

Medicare patients

366

Average age 75

Services billed

2,262

81 women, 285 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 42%
Ischemic heart disease 42%
Chronic kidney disease 37%
Depression 21%
Heart failure 17%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTANDI
  • Astellas Pharma US Inc $132
  • PFIZER INC. $15
$147 25 —
PYLARIFY
  • Progenics Pharmaceuticals, Inc. $98
$98 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $75
$75 — —
BOTOX
  • AbbVie, Inc. $63
$63 — —
LUPRON DEPOT
  • AbbVie, Inc. $58
$58 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

309 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record